Antoni Ribas, MD, PhD

You are here

Antoni Ribas, MD, PhD


MSTP role: 
Selected faculty

Antoni Ribas, MD, PhDProfessor of Medicine, Professor of Surgery and Professor of Molecular and Medical Pharmacology Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC)Chair of the Melanoma Committee at SWOG


Trained at the University of Barcelona, with postdoctoral research and clinical fellowships at UCLA. Dr Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA.

His NCI, State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients. He has been instrumental in the clinical development of several agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), cobimetinib (Cotellic), dabrafenib (Tafinlar) and trametinib (Mekinist). He is an elected member of the American Society of Clinical Investigation (ASCI), the recipient of the AACR Richard and Hinda Rosenthal Award and a National Cancer Institute (NCI) Outstanding Investigator Award.